Primary Thromboprophylaxis in Antiphospholipid Syndrome with Concurrent Breast Cancer Treatment

<aside> Clinical Recommendation Summary: For a 36-year-old woman with recurrent pregnancy loss, persistent antiphospholipid antibody positivity, no history of thrombosis, recent breast cancer surgery, and planned long-term tamoxifen therapy with a Khorana score of 1, low-dose aspirin (75-100 mg daily) is the evidence-based recommended choice for primary thromboprophylaxis.

</aside>

Clinical Case Details

Evidence-Based Analysis

Antiphospholipid Syndrome Guidelines

<aside> EULAR 2019 Recommendations:

• Asymptomatic aPL carriers with high-risk profiles should receive low-dose aspirin (75-100 mg daily)
• Non-pregnant women with obstetric APS history should receive prophylactic low-dose aspirin after risk/benefit evaluation
• High-risk aPL profiles include persistent lupus anticoagulant, double/triple positive aPL, or high-titre aPL </aside>

Evidence Limitations: Only one RCT has evaluated aspirin for preventing first thrombotic events in persistently aPL-positive individuals without thrombosis history (HR 1.04, 95% CI 0.69-1.56).

Cancer-Related Thromboprophylaxis

<aside> ASCO 2019 Guidelines:

• Routine pharmacologic thromboprophylaxis not recommended for all cancer outpatients
• High-risk outpatients (Khorana score ≥2) may receive apixaban, rivaroxaban, or LMWH
• Intermediate risk patients (Khorana score of 1) do not meet threshold for routine anticoagulation </aside>

ASH 2021 Guidelines: For ambulatory cancer patients at intermediate risk receiving systemic therapy, ASH suggests no prophylaxis over parenteral prophylaxis.

Tamoxifen-Associated VTE Risk

Clinical Context: While tamoxifen significantly increases relative VTE risk, the absolute risk remains relatively low, particularly in younger women without additional risk factors.

Pregnancy-Specific Considerations

<aside> ACCP 2012 Guidelines: For women with obstetric APS (≥3 pregnancy losses), recommend antepartum LMWH plus low-dose aspirin (75-100 mg/day) during pregnancy (Grade 1B evidence).

</aside>

Integrated Clinical Recommendation

<aside> Primary Recommendation: Low-dose aspirin (75-100 mg daily) is the appropriate thromboprophylaxis strategy for this patient.

</aside>

• Rationale for Low-Dose Aspirin
• Conditions When Anticoagulation Would Be Indicated

Management Algorithm

flowchart TD
    A["Patient with APS and Breast Cancer"] --> B{"Thrombosis History?"}
    B -- "Yes" --> C["Secondary Prevention:\\nTherapeutic Anticoagulation"]
    B -- "No" --> D{"Khorana Score?"}
    D -- "≥2" --> E["Consider DOAC or LMWH\\n(per ASCO/ASH guidelines)"]
    D -- "0-1" --> F["Low-Dose Aspirin\\n(75-100 mg daily)"]
    F --> G{"Pregnancy?"}
    G -- "Yes" --> H["Switch to LMWH + Aspirin\\n(per ACCP guidelines)"]
    G -- "No" --> I["Continue Aspirin\\nMonitor regularly"]
    I --> J{"New Risk Factors\\nor Events?"}
    J -- "Yes" --> K["Reassess Risk\\nConsider Anticoagulation"]
    J -- "No" --> I

Monitoring & Follow-up Considerations

Clinical Monitoring

• Regular assessment of bleeding risk factors
• Periodic reassessment of thrombotic risk profile
• Monitor for signs/symptoms of VTE
• 3-monthly review during first year of tamoxifen

Multidisciplinary Coordination

• Coordinate between oncology, haematology, and primary care
• Clear communication of thromboprophylaxis strategy
• Ensure consistent approach across specialties
• Document decision-making rationale

Patient Education